10 Predictions for Precision Medicine in 2017 | Diaceutics

10 Predictions for Precision Medicine in 2017

December 20th, 2016

sign direction future-future made in 2d software

When a new year arrives many of us make lists about giving up this or starting that, but at Diaceutics we write a list about what we think will happen in the world of precision medicine (PM) and targeted therapies. In an ever-changing diagnostic landscape there are plenty to choose from but here are our top ten predictions.

 

  1. Patient empowerment and patient centric approaches
    It’s easy to forget that the most important element of PM is the patient and yet they are often sidelined. Diaceutics has long advocated putting the patient first but we hope to see a shift in this area in 2017. We might see a new patient activist group (supported by TedMed or a technology group) that is focused on better patient education for testing and treatment in PM. Right now, patients are unhappy about being the ignored stakeholder in complex targeted therapy rollouts like anti-PD-1 therapy, so a move towards patient centricity is overdue.
  1. Big data
    Big data analytics of healthcare outcomes, electronic health records and, with that, patient data privacy will definitely be on the agenda for 2017 and beyond. We predict that patient advocacy groups will join the voices calling for data privacy protection.
  1. Wearables
    Wearable technology is becoming standard lifestyle kit but we’ll see its impact in healthcare, too. We expect greater integration of predictive wearables into key diagnostic treatment pathways with the rise of strong, well-funded wearable and tracking technology companies such as Livongo.
  1. Targeted therapies for AML
    There will be much discussion around the launch of new acute myeloid leukemia (AML) therapies. After a 20 to 30 year wait, patients will finally have a number of new treatment options.
  1. POC Dx for infectious diseases
    We expect a rise in rapid testing and point of care diagnostics for the screening of infectious diseases and the monitoring of chronic diseases, as medical research teams up with the communication and technology world.
  1. Continued use of LDTs
    Pharma will have to manage laboratory developed tests (LDTs) alongside IVD kits in the face of the FDA’s likely postponement (or in reality, the binning) of the LDT draft guidance. This will trigger different types of laboratory partnering agreements in 2017.
  1. Immunotherapy
    Mutational load testing in immunotherapy for cancer will secure a prominent place alongside established cancer treatments as approvals of, for example, PD-1 therapies, continue to rise.
  1. Liquid biopsies
    There is increasing evidence of more laboratory adoption of liquid biopsies, in which a non-invasive blood test is used to detect cancer cells.
  1. Dx Futures Index
    An analysis of the major contribution that diagnostics make to pharma share value will trigger the publication of a ‘pharma readiness for Dx’ investment futures index.
  1. A sudden departure
    Finally, we predict that a major diagnostic company will exit a companion Dx-pharma collaboration due to lack of royalties from enabled therapy sales.

With so much happening on the horizon this could be a big year for diagnostics. Diaceutics has already made detailed analyses of the 2016 space in its new Pharma Readiness for Dx Index which also includes forecasts not just for 2017 but the next few years to come. For more information and detailed predictions listen to our webinar: Which pharma companies are Dx ready for precision medicine in 2017? Benchmarking, financial risks and predictions.

0e5695f7-d8d9-489c-aaf5-afd34ced12cb

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn